Evidence map›Paper›PMID 21814496›Full record

ArticlePLoS medicine2011

Is scale-up worth it? Challenges in economic analysis of diagnostic tests for tuberculosis.

David W Dowdy, Adithya Cattamanchi, Karen R Steingart, Madhukar Pai

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PLoS medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03044158 (GeneXpert Performance Evaluation for Linkage to Tuberculosis Care), which is not on this map. Cited by 39 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03044158 nacompletednot on this mapstarted 2018, after this paper: background citation

GeneXpert Performance Evaluation for Linkage to Tuberculosis Care: The XPEL-TB Trial

TypeinterventionalSponsorUniversity of California, San FranciscoRan2018 to 2022Enrolled10,644ConditionsTuberculosis, Pulmonary, Rifampicin Resistant TuberculosisArmsGeneXpert I, Process re-design, Performance Feedback
3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. A guide to aid the selection of diagnostic tests.Bulletin of the World Health Organization · 2017
    Article
  17. Article
  18. Article
  19. Article
  20. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

David W DowdyDepartment of Medicine, University of California, San Francisco, California, United States of America. ddowdy@jhsph.edu
Adithya Cattamanchi
Karen R Steingart
Madhukar Pai

Funding

Immunodiagnosis of Active Tuberculosis in HIV-infected PatientsK23HL094141 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CATTAMANCHI, ADITHYA · 2009 to 2013
$760k
CIHRNHLBI NIH HHS K23 HL094141
6 · The paper itself

Abstract

David Dowdy and colleagues discuss the complexities of costing new TB diagnostic tests, including GeneXpert, and argue that flexible analytic tools are needed for decision-makers to adapt large-sample cost-effectiveness data to local conditions.

Indexed as

Cost-Benefit AnalysisFalse Positive ReactionsHumansMolecular Diagnostic TechniquesMycobacterium tuberculosisPolymerase Chain ReactionSensitivity and SpecificityTuberculosis, Pulmonary

Identifiers

PMID21814496
PMCPMC3144197

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.